Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.66 |
| ▸ | FNTB | P49356 | 16/20 | 0.66 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925962 | 0.94 | FNTA (0.70) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6599415 | 0.91 | FNTA (0.69) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6926512 | 0.91 | FNTA (0.72) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6924592 | 0.90 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6925574 | 0.90 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6927052 | 0.89 | FNTA (0.67) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6600740 | 0.88 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6983464 | 0.88 | FNTA (0.69) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6972800 | 0.86 | FNTA (0.68) | FNTAFNTBPGGT1BCYP3A4HTR2C | |
| SCHEMBL6928267 | 0.85 | FNTA (0.70) | FNTAFNTBPGGT1BCYP3A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169320-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2004-09-22 | — | — | EP | disclosed |
| US-6511978-B1 | For treating cancer, restenosis, atherosclerosis or viral infections | LG LIFE SCIENCES, LTD. (KR) | 2003-01-28 | — | — | US | disclosed |